Conversion from troglitazone to rosiglitazone or pioglitazone in the VA: A multicenter DUE

Formulary

Volumn 39, Issue 6, 2004, Pages 310-317

  Burk, Muriel ^a   Morreale, Anthony P ^b   Cunningham, Francesca ^a,c  

^a VA Pharm Benefits Mgmt S H G   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE;

ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE CALCULATION; DRUG SAFETY; DRUG UTILIZATION; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; GOVERNMENT; HEMATOCRIT; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACY BENEFIT MANAGER; SOMNOLENCE; SYSTEMATIC REVIEW; WEIGHT GAIN;

EID: 2942668406     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes. Diabetes. 1996;45:1661-1669.
2. Avandia [package insert]. Research Triangle Park, NC; GlaxoSmithKline Pharmaceuticals; 2003.
3. Actos [package insert]. Indianapolis, Ind: Eli Lilly/Takeda; 2003.
4. American Diabetes Association. Clinical practice recommendations 2002. Diabetes Care. 2002;25 Suppl 1:S1-S147.
5. D'Arrigo T. Glitazones: treatment or trouble? Diabetes Forecast. February 2000;64-66.
6. King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care. 2000;23(4):557.
7. Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel. Criteria for Non-Formulary Use of Thiazolidinediones. Washington, DC: Veterans Health Administration, Department of Veterans Affairs; May 2000.